**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 64143

**Manuscript Type:** MINIREVIEWS

**Associating liver partition and portal vein ligation for staged hepatectomy in the treatment of colorectal cancer liver metastases**

Wen XD *et al*. ALPPS in the treatment of CRLM

Xu-Dong Wen, Le Xiao

**Xu-Dong Wen,** Department of Gastroenterology and Hepatology, Chengdu First People’s Hospital, Chengdu 610016, Sichuan Province, China

**Le Xiao,** General Surgery Center, The General Hospital of Western Theater Command, Chengdu 610083, Sichuan Province, China

**Author contributions:** Wen XD participated in the writing of the main manuscript; Xiao L designed the outline and performed the revision of the manuscript.

**Supported by** the Sichuan Provincial Science and Technology Department Application Foundation Project, No. 2021YJ0198; Scientific Research Project of Sichuan Provincial Health Commission, No. 20PJ196; and Research Foundation of Chengdu Medical College, No. CYZ19-07.

**Corresponding author: Le Xiao, MD, Surgeon,** General Surgery Center, The General Hospital of Western Theater Command, No. 270 Rongdu Avenue, Jinniu District, Chengdu 610083, Sichuan Province, China. xiaole007@sina.com

**Received:** February 9, 2021

**Revised:** May 24, 2021

**Accepted:** July 13, 2021

**Published online:**

**Abstract**

Colorectal cancer (CRC) is a common malignancy of the digestive system. Colorectal liver cancer metastasis (CRLM) occurs in approximately 50% of the patients and is the main cause of CRC mortality. Surgical resection is currently the most effective treatment for CRLM. However, given that the remnant liver volume after resection should be adequate, only a few patients are suitable for radical resection. Since Dr. Hans Schlitt first performed the associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for CRLM in 2012, ALPPS has received considerable attention and has continually evolved in recent years. This review explains the technical origin of the ALPPS procedure for CRLM and evaluates its efficacy, pointing to its favorable postoperative outcomes. We also discuss the patient screening strategies and optimization of ALPPS to ensure long-term survival of patients with CRLM in whom surgery cannot be performed. Finally, further directions in both basic and clinical research regarding ALPPS have been proposed. Although ALPPS surgery is a difficult and high-risk technique, it is still worth exploration by experienced surgeons.

**Key Words:** Associating liver partition and portal vein ligation for staged hepatectomy; Colorectal liver cancer metastases; Portal embolization; Portal ligation; Two-stage hepatectomy

Wen XD, Xiao L. Associating liver partition and portal vein ligation for staged hepatectomy in the treatment of colorectal cancer liver metastases. *World J Gastrointest Surg* 2021; In press

**Core Tip:** Several previous reviews have discussed the associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) technique and its applications. However, this is the first review on ALPPS in colorectal liver cancer metastasis, in which the technical evolution of the procedure is described, its safety and efficacy are evaluated, patient selection process and technique improvement are discussed, and further directions are proposed.

**INTRODUCTION**

Colorectal cancer (CRC) is a common malignancy of the digestive system and is the third and second most common cancer in males and females, respectively. CRC forms metastases in the liver in 50% of patients, and approximately 15% to 25% of patients have concurrent colorectal liver cancer metastases (CRLM) at initial diagnosis, while nearly 25% of the patients have metachronous CRLM after colectomy. The median survival time in untreated patients is less than 6.9 mo[1,2]. Surgical resection is currently recognized as the most effective treatment for CRLM. Complete resection of the liver metastases improves patient outcomes, with the median survival time increasing to 35 mo and the 5-year survival rate ranging from 30% to 57%[3]. Therefore, a comprehensive evaluation of the technique by a multidisciplinary team followed by an increase in the rate of surgical resection could effectively improve the survival rate of patients suffering from CRLM[4].

Patients with multiple liver metastases located on one side of the liver usually require extensive hepatectomy; however, a sufficient volume of the remnant liver must be preserved in these patients, making radical resection virtually impossible in patients with CRLM[5,6]. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) was first reported in 2012 in the context of resection of advanced tumors. The procedure is considered a revolutionary breakthrough in hepatobiliary surgery because of its remarkable curative effect by inducing hypertrophy of the liver in a short time[7]. The application of ALPPS in patients with CRC, who were considered unsuitable for radical surgery in the past, has shown therapeutic promise. Although ALPPS has been used in patients with cholangiocarcinoma, hepatocellular carcinoma, and neuroendocrine tumors with liver metastasis, ALPPS is most commonly performed in patients with CRLM.

As a new surgical technique, and despite its encouraging efficacy, ALPPS has been the subject of debate. In the early years of the ALPPS procedure, the surgical complications and mortality rates ranged from 40% to 64% and 22% to 29%, respectively. These high rates were considered to be primarily due to the evolving surgical technique and improper case selection. More recently, questions about whether improvement in the quality of life and survival benefits of the procedure balance the risks of complications and death have been raised[8]. However, with the development of the ALPPS procedure, an increasing number of patients with CRLM have undergone radical resection and survived for a long time afterwards; this has provided new hope to patients considered unsuitable for surgery. Thus, it is necessary to further standardize the technical methodology of ALPPS, summarize the technical points and preventive measures for complications, and optimize patient selection strategies. In this study, we will evaluate and review the current therapeutic value of ALPPS for CRLM.

**BACKGROUND AND ORIGIN**

Portal vein embolization or ligation (PVE/PVL) is used to increase the volume of the future remnant lobe of the liver to a safe range before two-stage hepatectomy (TSH). This increases the liver volume so that more patients can undergo radical hepatectomy. Following the PVE procedure, it takes approximately 6–8 wk for the liver to regenerate by 20%–46%. However, due to the spread or progression of the tumor during the waiting period, one-third of patients become ineligible for second-stage radical resection[7]. As a result, most patients have to undergo interventional therapy, radiofrequency ablation, or other non-surgical methods.

In 2007, Dr. Hans Schlitt from Regensburg, Germany, planned to perform right hepatectomy for a patient with hilar cholangiocarcinoma[9]. During the surgery, he found that the future remnant liver volume would be inadequate and temporarily decided to perform selective hepaticojejunostomy on the left biliary system. To completely expose the left hepatic duct to facilitate hepaticojejunostomy, he had to split the liver parenchyma between the left medial lobe and the left lateral lobe along the falciform ligament and ligate the right portal vein to induce hypertrophy of the left lobe of the liver. On the 8th d after surgery, computed tomography indicated that the left lobe had significantly enlarged; thus, the right lobe could be resected. Based on this finding, Dr. Hans Schlitt attempted to implement this new strategy in a CRLM patient with inadequate liver volume for radical tumor resection. This was the earliest record of the application of ALPPS to treat CRLM. In 2012, Schnitzbauer *et al*[10] reported 25 cases of patients who underwent this procedure, which attracted widespread interest and attention. This technique was later abbreviated as ALPPS.

**TECHNIQUE AND IMPROVEMENT**

ALPPS is mainly performed in patients with CRLM, primary liver cancer, hilar cholangiocarcinoma, breast cancer liver metastasis, and neuroendocrine cancer liver metastasis; however, it has been mainly used for CRLM due to its favorable oncological characteristics. The initial reported incidence of postoperative complications and mortality was 40%–64% and 22%–29%, respectively[8]. Analyses of postoperative complications revealed that the liver section is prone to cause bile leakage and that secondary infection is the main cause of mortality after surgery[11,12]. Hence, further technical improvements mainly focused on reducing cross-sectional bile leakage and infection, simplifying the surgery, and facilitating second-stage surgery. Currently, at the initial stage, the liver is wrapped with sterile plastic bags to collect bile and prevent bile peritonitis[13]. Moreover, some surgeons use radiofrequency and microwave ablation to complete liver parenchymal isolation in the first step of the surgery, which promotes hypertrophy of the future remnant liver, increasing its size by 62.3%[14]. Petrowsky *et al*[15] reported that ligation of at least 50% of the liver parenchyma could result in considerable liver proliferation. Favorable liver proliferation can also be achieved by intraoperative ultrasound confirmation that the blood flow between the segments is completely cut off and by placing a circumferential hepatic belt around the liver to block the blood vessels between the two segments[16].

The application of the anterior approach method to cut off the liver or to use the “hybrid ALPPS” method for postsurgical PVE when the portal vein is difficult to separate is more in line with the “No Touch” principle, thereby reducing the probability of tumor spread[17,18]. To adapt the procedure for tumor removal on the left side or even other parts of the liver, traditional hepatectomy has been modified to left-sided ALPPS and monosegment future liver remnant ALPPS. Many scholars believe that patients can benefit from laparoscopic ALPPS, stage 1 laparoscopy ALPPS, stage 2 open surgery, and full laparoscopic ALPPS[19,20]. However, currently, ALPPS is mainly performed by open surgery. Due to differences between various surgical facilities, the current development of ALPPS technology is mainly focused on achieving portal vein branch blockade and liver isolation and on simplifying the surgery. Thus, the surgical method is selected according to the tumor growth characteristics and expertise of the performing surgeon (Table 1).

**EFFICACY OF ALPPS IN THE TREATMENT OF CRLM**

In recent years, continuous technical optimization of ALPPS has significantly reduced the incidence of associated postoperative complications and mortality. Hernandez-Alejandro *et al*[21] reported 14 patients with CRLM who underwent the first stage of ALPPS, and all patients successfully underwent the second stage of surgery. The incidence of postoperative complications above Clavien–Dindo grade IIIB was 14%, and no perioperative deaths were reported. In 2014, Schadde *et al*[22] analyzed the data of 202 patients who underwent ALPPS and who were registered in the international ALPPS.net database (including 141 patients with CRLM). The results revealed that the median interval between the two steps of the surgery was 7 d, median growth of the remnant liver volume was 80%, incidence of serious complications (Clavien–Dindo grade ≥ IIIB) was 27%, and mortality rate was 9%. All 141 cases with CRLM had good oncological results, which demonstrated that CRLM patients under 60 years of age were most likely to benefit from ALPPS. A study on the postoperative quality of life found that patients had an excellent quality of life after ALPPS, equivalent to that of healthy people[23].

The comparative results between ALPPS and traditional TSH for the treatment of CRLM are remarkable. A study compared 48 patients who underwent ALPPS and 83 who underwent TSH for initially unresectable advanced CRLM. The proportion of patients who underwent second-stage surgical resection was significantly higher in the ALPPS group than in the TSH group, and there was no increase in the recurrence of early-stage tumors[22]. The LIGRO Trial, a high-quality randomized controlled trial, further proved that ALPPS could achieve higher resectability than TSH in patients with advanced CRLM, with a comparable perioperative complication rate[24]. In 2020, Petrowsky *et al*[25] retrospectively analyzed the efficacy of ALPPS in 510 patients with CRLM in 22 centers over the past 10 years. The median cancer-specific survival (CSS) time, overall survival time, and recurrence-free survival time were 42, 37, and 11 mo, respectively (Figure 1). This large cohort provided the first convincing evidence that patients with unresectable CRLM who underwent ALPPS not only had low perioperative mortality but also achieved satisfactory long-term oncological outcomes. This was especially seen in patients with good tumor biobehavior and response to chemotherapy (Table 2). Moreover, on multivariate analysis, tumor characteristics (primary T4, right colon), biological characteristics (K/N-RAS status), and chemotherapy response (solid tumor response evaluation criteria) were found to be independent predictors of CSS, while the occurrence of serious surgical complications indicated a poor prognosis. These findings stress the importance of proper patient screening and the selection of suitable surgical methods. However, the comparability of data is limited as there are considerable differences in indications and patient selection methods between TSH and ALPPS in various therapeutic centers. Whether ALPPS should be an auxiliary tool for patients with unsuccessful TSH or a more optimal choice for patients with TSH requires long-term and systematic studies and evaluation.

**PATIENT SCREENING STRATEGY**

Strict and uniform patient selection and optimization of surgical methods could effectively reduce the complication and mortality rates of ALPPS in the treatment of CRLM. In light of the high 90-d mortality rate of simultaneous ALPPS and colorectal resection (15%), Wanis *et al*[26] recommended against simultaneous ALPPS and colorectal resection. However, a study on a large cohort of patients found that resection of primary colorectal lesions during primary ALPPS surgery did not increase the perioperative mortality rate[25]. Thus, ALPPS can be considered in simultaneous or heterogeneous CRLM with the likelihood of inadequate future remnant liver volume. Current clinical trials have not conclusively shown whether preoperative chemotherapy or direct surgery is beneficial for the survival of CRLM patients; nevertheless, preoperative chemotherapy remains an option for patients with poor tumor biology and surgical tolerance.

We believe that empirical surgical indications for ALPPS in the treatment of CRLM should be limited to the following situations: patients with good overall condition, with good liver function, and ability to tolerate large-volume liver resection; patients with extensive left/right liver metastases that require large hemihepatic or hepatic trilobe resection with the future remnant liver volume likely to be less than 30% of that before surgery; patients with no evidence of metastasis to organs other than the liver, in whom surgery could technically achieve an R0 resection; cases in which the tumor does not invade the main portal vein of the liver and there is no tumor thrombus; and patients who are fully or partially sensitive to systemic chemotherapy and have stopped chemotherapy for more than 4 wk. Before the second ALPPS stage, careful attention should be paid to the functional evaluation of the hyperplastic liver and the overall condition of the patient after first-stage ALPPS, including recovery from serious complications and the patient’s nutritional status. A model for end-stage liver disease score of less than 10 is the deciding indication for stage 2 surgery. The majority of CRLM patients reportedly have a history of chemotherapy prior to undergoing ALPPS. Existing evidence suggests that chemotherapy has no significant inhibitory effect on the hypertrophy of the future remnant liver. However, it is important to rule out sinusoidal obstruction syndrome and decreased liver reserve ability caused by chemotherapeutic drugs such as oxaliplatin.

For patients with CRLM in whom ALPPS is being considered, the first step is to determine whether they have technically resectable tumors. The oncological characteristics of the tumor are used to determine whether tumors suitable for resection should be treated with direct surgery or neoadjuvant chemotherapy, while conversion therapy can be used for unresectable tumors. It should be noted that resectability is a partially subjective judgment made by hepatobiliary surgeons; therefore, differences in opinion as well as significant differences in methods and efficacy are seen across surgical centers worldwide. Individualized technical judgments should be made based on the technical ability of the surgeon and following a joint discussion on oncological characteristics of a given case by a multidisciplinary surgical team.

**PROSPECT**

In a comparison of liver proliferation in clinical and pre-clinical trials, the liver growth rate following ALPPS was 11 times higher than that after pulmonary vein obstruction (PVO)[22], and the hepatocyte proliferation rate was 10 times higher than that after portal vein ligation (PLV)[27]. Thus, the combination of portal vein branch ligation and liver isolation appears to trigger rapid growth of the remnant liver by an unknown mechanism. It has been hypothesized that this rapid growth could be due to the following factors: hemodynamic changes after PVO[28,29], inflammatory stimulation as a result of local trauma caused by liver separation[27,30], and activation of specific signaling pathways that lead to significant liver regeneration after ALPPS[31-33]. The results of early research have partially confirmed the importance of the abovementioned factors, which are likely to jointly contribute to hepatic growth. Results of a breakthrough research on the mechanism of liver regeneration and CRLM metastasis could simplify the surgery, reduce the rapid increase in the size of the remnant liver induced by surgery, or inhibit malignant progression during the process of liver regeneration. Treatment of CRLM using ALPPS has created an excellent research platform, which provides the possibility for an in-depth study of tumor growth and metastasis patterns during liver regeneration.

The favorable outcomes of ALPPS in the treatment of CRLM encourage surgeons to attempt technical optimization strategies. However, given the small number of ALPPS cases performed in a single center and differences in technical preferences of surgeons, standardized surgical procedures require long-term exploration and optimization. A large-scale comparative study of different ALPPS methods and a more detailed meta-analysis of the data of registered cases in the ALPPS.net database might facilitate the ongoing process of ALPPS evaluation. ALPPS remains a complex and challenging surgery and most surgeons consider it an auxiliary tool in the treatment of CRLM rather than as the first choice. Selecting CRLM patients who can achieve maximum benefit from this approach is challenging, but important. Currently, the ALPPS risk score can be used to predict the risk of related complications. Based on the oncological outcomes of ALPPS treatment for CRLM, the standardization of other evaluation indicators or grading systems can help avoid the unnecessary use of ALPPS.

**CONCLUSION**

CRLM with the likelihood of a low future remnant liver volume is considered a good indication for ALPPS. Existing research on ALPPS has proven the technique to be safe, effective, and associated with favorable therapeutic outcomes. It is expected that with meticulous patient screening and optimization of surgical methods, ALPPS will be considered appropriate for a large number of patients with CRLM who are considered ineligible for surgery. Although ALPPS is a difficult and high-risk technique, it is still worth exploration by experienced surgeons.

**REFERENCES**

1 **Shimada H**, Tanaka K, Endou I, Ichikawa Y. Treatment for colorectal liver metastases: a review. *Langenbecks Arch Surg* 2009; **394**: 973-983 [PMID: 19582473 DOI: 10.1007/s00423-009-0530-8]

2 **Gallinger S**, Biagi JJ, Fletcher GG, Nhan C, Ruo L, McLeod RS. Liver resection for colorectal cancer metastases. *Curr Oncol* 2013; **20**: e255-e265 [PMID: 23737695 DOI: 10.3747/co.20.1341]

3 **de Jong MC**, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, Choti MA, Aldrighetti L, Capussotti L, Pawlik TM. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. *Ann Surg* 2009; **250**: 440-448 [PMID: 19730175 DOI: 10.1097/SLA.0b013e3181b4539b]

4 **Margonis GA**, Sergentanis TN, Ntanasis-Stathopoulos I, Andreatos N, Tzanninis IG, Sasaki K, Psaltopoulou T, Wang J, Buettner S, Papalois ΑE, He J, Wolfgang CL, Pawlik TM, Weiss MJ. Impact of Surgical Margin Width on Recurrence and Overall Survival Following R0 Hepatic Resection of Colorectal Metastases: A Systematic Review and Meta-analysis. *Ann Surg* 2018; **267**: 1047-1055 [PMID: 29189379 DOI: 10.1097/SLA.0000000000002552]

5 **Leporrier J**, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. *Br J Surg* 2006; **93**: 465-474 [PMID: 16523446 DOI: 10.1002/bjs.5278]

6 **Manfredi S**, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. *Ann Surg* 2006; **244**: 254-259 [PMID: 16858188 DOI: 10.1097/01.sla.0000217629.94941.cf]

7 **Baumgart J,** Lang S, Lang H. A new method for induction of liver hypertrophy prior to right trisectionectomy: A report of three cases. *HPB* 2011; **13**: 71-72

8 **Hasselgren K**, Sandström P, Björnsson B. Role of associating liver partition and portal vein ligation for staged hepatectomy in colorectal liver metastases: a review. *World J Gastroenterol* 2015; **21**: 4491-4498 [PMID: 25914457 DOI: 10.3748/wjg.v21.i15.4491]

9 **de Santibañes E**, Clavien PA. Playing Play-Doh to prevent postoperative liver failure: the "ALPPS" approach. *Ann Surg* 2012; **255**: 415-417 [PMID: 22330039 DOI: 10.1097/SLA.0b013e318248577d]

10 **Schnitzbauer AA**, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, Fichtner-Feigl S, Lorf T, Goralcyk A, Hörbelt R, Kroemer A, Loss M, Rümmele P, Scherer MN, Padberg W, Königsrainer A, Lang H, Obed A, Schlitt HJ. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. *Ann Surg* 2012; **255**: 405-414 [PMID: 22330038 DOI: 10.1097/SLA.0b013e31824856f5]

11 **Alvarez FA**, Ardiles V, Sanchez Claria R, Pekolj J, de Santibañes E. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): tips and tricks. *J Gastrointest Surg* 2013; **17**: 814-821 [PMID: 23188224 DOI: 10.1007/s11605-012-2092-2]

12 **Andriani OC**. Long-term results with associating liver partition and portal vein ligation for staged hepatectomy (ALPPS). *Ann Surg* 2012; **256**: e5; author reply e16-e5; author reply e19 [PMID: 22842129 DOI: 10.1097/SLA.0b013e318265fbbe]

13 **Torres OJ**, Moraes-Junior JM, Lima e Lima NC, Moraes AM. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): a new approach in liver resections. *Arq Bras Cir Dig* 2012; **25**: 290-292 [PMID: 23411931 DOI: 10.1590/s0102-67202012000400015]

14 **Gall TM**, Sodergren MH, Frampton AE, Fan R, Spalding DR, Habib NA, Pai M, Jackson JE, Tait P, Jiao LR. Radio-frequency-assisted Liver Partition with Portal vein ligation (RALPP) for liver regeneration. *Ann Surg* 2015; **261**: e45-e46 [PMID: 24670841 DOI: 10.1097/SLA.0000000000000607]

15 **Petrowsky H**, Györi G, de Oliveira M, Lesurtel M, Clavien PA. Is partial-ALPPS safer than ALPPS? A single-center experience. *Ann Surg* 2015; **261**: e90-e92 [PMID: 25706390 DOI: 10.1097/SLA.0000000000001087]

16 **Robles Campos R**, Parrilla Paricio P, López Conesa A, Brusadín R, López López V, Jimeno Griñó P, Fuster Quiñonero M, García López JA, de la Peña Moral J. [A new surgical technique for extended right hepatectomy: tourniquet in the umbilical fissure and right portal vein occlusion (ALTPS). Clinical case]. *Cir Esp* 2013; **91**: 633-637 [PMID: 24246509 DOI: 10.1016/j.ciresp.2013.09.004]

17 **Vennarecci G**, Levi Sandri GB, Ettorre GM. Performing the ALPPS Procedure by Anterior Approach and Liver Hanging Maneuver. *Ann Surg* 2016; **263**: e11 [PMID: 25371131 DOI: 10.1097/SLA.0000000000001007]

18 **Li J**, Kantas A, Ittrich H, Koops A, Achilles EG, Fischer L, Nashan B. Avoid "All-Touch" by Hybrid ALPPS to Achieve Oncological Efficacy. *Ann Surg* 2016; **263**: e6-e7 [PMID: 25072445 DOI: 10.1097/SLA.0000000000000845]

19 **Brustia R**, Scatton O, Perdigao F, El-Mouhadi S, Cauchy F, Soubrane O. Vessel identifications tags for open or laparoscopic associating liver partition and portal vein ligation for staged hepatectomy. *J Am Coll Surg* 2013; **217**: e51-e55 [PMID: 24246632 DOI: 10.1016/j.jamcollsurg.2013.08.020]

20 **Xiao L**, Li JW, Zheng SG. Totally laparoscopic ALPPS in the treatment of cirrhotic hepatocellular carcinoma. *Surg Endosc* 2015; **29**: 2800-2801 [PMID: 25515978 DOI: 10.1007/s00464-014-4000-1]

21 **Hernandez-Alejandro R**, Bertens KA, Pineda-Solis K, Croome KP. Can we improve the morbidity and mortality associated with the associating liver partition with portal vein ligation for staged hepatectomy (ALPPS) procedure in the management of colorectal liver metastases? *Surgery* 2015; **157**: 194-201 [PMID: 25282528 DOI: 10.1016/j.surg.2014.08.041]

22 **Schadde E**, Ardiles V, Slankamenac K, Tschuor C, Sergeant G, Amacker N, Baumgart J, Croome K, Hernandez-Alejandro R, Lang H, de Santibaňes E, Clavien PA. ALPPS offers a better chance of complete resection in patients with primarily unresectable liver tumors compared with conventional-staged hepatectomies: results of a multicenter analysis. *World J Surg* 2014; **38**: 1510-1519 [PMID: 24748319 DOI: 10.1007/s00268-014-2513-3]

23 **Wanis KN**, Ardiles V, Alvarez FA, Tun-Abraham ME, Linehan D, de Santibañes E, Hernandez-Alejandro R. Intermediate-term survival and quality of life outcomes in patients with advanced colorectal liver metastases undergoing associating liver partition and portal vein ligation for staged hepatectomy. *Surgery* 2018; **163**: 691-697 [PMID: 29203284 DOI: 10.1016/j.surg.2017.09.044]

24 **Sandström P**, Røsok BI, Sparrelid E, Larsen PN, Larsson AL, Lindell G, Schultz NA, Bjørnbeth BA, Isaksson B, Rizell M, Björnsson B. ALPPS Improves Resectability Compared With Conventional Two-stage Hepatectomy in Patients With Advanced Colorectal Liver Metastasis: Results From a Scandinavian Multicenter Randomized Controlled Trial (LIGRO Trial). *Ann Surg* 2018; **267**: 833-840 [PMID: 28902669 DOI: 10.1097/SLA.0000000000002511]

25 **Petrowsky H**, Linecker M, Raptis DA, Kuemmerli C, Fritsch R, Kirimker OE, Balci D, Ratti F, Aldrighetti L, Voskanyan S, Tomassini F, Troisi RI, Bednarsch J, Lurje G, Fard-Aghaie MH, Reese T, Oldhafer KJ, Ghamarnejad O, Mehrabi A, Abraham MET, Truant S, Pruvot FR, Hoti E, Kambakamba P, Capobianco I, Nadalin S, Fernandes ESM, Kron P, Lodge P, Olthof PB, van Gulik T, Castro-Benitez C, Adam R, Machado MA, Teutsch M, Li J, Scherer MN, Schlitt HJ, Ardiles V, de Santibañes E, Brusadin R, Lopez-Lopez V, Robles-Campos R, Malagó M, Hernandez-Alejandro R, Clavien PA. First Long-term Oncologic Results of the ALPPS Procedure in a Large Cohort of Patients With Colorectal Liver Metastases. *Ann Surg* 2020; **272**: 793-800 [PMID: 32833765 DOI: 10.1097/SLA.0000000000004330]

26 **Wanis KN**, Buac S, Linecker M, Ardiles V, Tun-Abraham ME, Robles-Campos R, Malago M, de Santibañes E, Clavien PA, Hernandez-Alejandro R. Patient Survival After Simultaneous ALPPS and Colorectal Resection. *World J Surg* 2017; **41**: 1119-1125 [PMID: 27837237 DOI: 10.1007/s00268-016-3818-1]

27 **Schlegel A**, Lesurtel M, Melloul E, Limani P, Tschuor C, Graf R, Humar B, Clavien PA. ALPPS: from human to mice highlighting accelerated and novel mechanisms of liver regeneration. *Ann Surg* 2014; **260**: 839-46; discussion 846-7 [PMID: 25379855 DOI: 10.1097/SLA.0000000000000949]

28 **Colak D**, Al-Harazi O, Mustafa OM, Meng F, Assiri AM, Dhar DK, Broering DC. RNA-Seq transcriptome profiling in three liver regeneration models in rats: comparative analysis of partial hepatectomy, ALLPS, and PVL. *Sci Rep* 2020; **10**: 5213 [PMID: 32251301 DOI: 10.1038/s41598-020-61826-1]

29 **Dhar DK**, Mohammad GH, Vyas S, Broering DC, Malago M. A novel rat model of liver regeneration: possible role of cytokine induced neutrophil chemoattractant-1 in augmented liver regeneration. *Ann Surg Innov Res* 2015; **9**: 11 [PMID: 26535054 DOI: 10.1186/s13022-015-0020-3]

30 **Yao L**, Li C, Ge X, Wang H, Xu K, Zhang A, Dong J. Establishment of a rat model of portal vein ligation combined with in situ splitting. *PLoS One* 2014; **9**: e105511 [PMID: 25144490 DOI: 10.1371/journal.pone.0105511]

31 **Langiewicz M**, Graf R, Humar B, Clavien PA. JNK1 induces hedgehog signaling from stellate cells to accelerate liver regeneration in mice. *J Hepatol* 2018; **69**: 666-675 [PMID: 29709677 DOI: 10.1016/j.jhep.2018.04.017]

32 **Otsuka N**, Yoshioka M, Abe Y, Nakagawa Y, Uchinami H, Yamamoto Y. Reg3α and Reg3β Expressions Followed by JAK2/STAT3 Activation Play a Pivotal Role in the Acceleration of Liver Hypertrophy in a Rat ALPPS Model. *Int J Mol Sci* 2020; **21** [PMID: 32517345 DOI: 10.3390/ijms21114077]

33 **Uribe M**, Uribe-Echevarría S, Mandiola C, Zapata MI, Riquelme F, Romanque P. Insight on ALPPS - Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy - mechanisms: activation of mTOR pathway. *HPB (Oxford)* 2018; **20**: 729-738 [PMID: 29571618 DOI: 10.1016/j.hpb.2018.02.636]

**Footnotes**

**Conflict-of-interest statement:** There is no conflict of interest associated with any of the senior authors or other coauthors who contributed to the preparation of this manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** February 9, 2021

**First decision:** May 13, 2021

**Article in press:**

**Specialty type:** Surgery

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Akbulut S **S-Editor:** Zhang H **L-Editor:** Filipodia **P-Editor:**

**Figure Legends**

****

**Figure 1 First long-term oncologic results of the** **associating liver partition and portal vein ligation for staged hepatectomy procedure in a large cohort of patients with colorectal liver metastases[25].** Kaplan–Meier plots for cancer-specific survival (CSS), overall survival (OS), and recurrence-free survival (RFS). The median CSS, OS, and RFS were 42, 37, and 11 mo, respectively. The 3- and 5-year CSS, OS, and RFS were 59%, 52%, and 19%, and 33%, 27%, and 12%, respectively. Citation: Petrowsky H, Linecker M, Raptis DA, Kuemmerli C, Fritsch R, Kirimker OE, Balci D, Ratti F, Aldrighetti L, Voskanyan S, Tomassini F, Troisi RI, Bednarsch J, Lurje G, Fard-Aghaie MH, Reese T, Oldhafer KJ, Ghamarnejad O, Mehrabi A, Abraham MET, Truant S, Pruvot FR, Hoti E, Kambakamba P, Capobianco I, Nadalin S, Fernandes ESM, Kron P, Lodge P, Olthof PB, van Gulik T, Castro-Benitez C, Adam R, Machado MA, Teutsch M, Li J, Scherer MN, Schlitt HJ, Ardiles V, de Santibañes E, Brusadin R, Lopez-Lopez V, Robles-Campos R, Malagó M, Hernandez-Alejandro R, Clavien PA. First long-term oncologic results of the ALPPS procedure in a large cohort of patients with colorectal liver metastases. Annals of surgery 2020; 272: 793-800. Copyright© 2020 Wolters Kluwer Health, Inc. **Table 1 Key modalities of the associating liver partition and portal vein ligation for staged hepatectomy technique**

|  |  |
| --- | --- |
| **ALPPS strategies** | **Technical points** |
| Classical ALPPS | Right portal vein ligation and right trisectionectomy |
| Rescue ALPPS | Failure of PVE with subsequent ALPPS |
| Laparoscopic ALPPS | Laparoscopy for stage 1 or both stages 1 and 2 |
| PVE ALPPS | The intentional use of PVE as part of the first stage is stated by using PVE-ALPPS |
| Partial ALPPS | Transection at least 50% of the future transection plane at stage 1 |
| Left ALPPS | Left portal vein ligation, left trisectionectomy |
| Tourniquet ALPPS | Tourniquet in the umbilical fissure and portal vein occlusion |
| Radiofrequency ALPPS | Radio-frequency-assisted liver partition |
| Microwave ALPPS | Microwave transection of the liver |
| Monosegment ALPPS | Extending hepatectomy, only sparing a single or adjacent segment |

ALPPS: Associating liver partition and portal vein ligation for staged hepatectomy; PVE: Portal vein embolization.

**Table 2 Outcome characteristics[25]**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Number of patients** | **Data completion** | **Value** |
| Interstage interval, d | 468 | 92% | 13 (9–21) |
| Stage 2 performed, *n* (%) | 510 | 100% | 492 (96) |
| R0 resection at stage 2, *n* (%) | 302 | 59% | 220 (73) |
| 90-d mortality, *n* (%) | 510 | 100% | 25 (5) |
| Complications ≥ 3B stage 1, *n* (%) | 501 | 98% | 37 (7) |
| Complications ≥ 3B stage 2, *n* (%) | 485 | 95% | 100 (21) |

The cohort included 510 patients with colorectal liver cancer metastasis who underwent associating liver partition and portal vein ligation for staged hepatectomy during the 10-year period from 2009 to 2019 in 22 international centers. Citation: Petrowsky H, Linecker M, Raptis DA, Kuemmerli C, Fritsch R, Kirimker OE, Balci D, Ratti F, Aldrighetti L, Voskanyan S, Tomassini F, Troisi RI, Bednarsch J, Lurje G, Fard-Aghaie MH, Reese T, Oldhafer KJ, Ghamarnejad O, Mehrabi A, Abraham MET, Truant S, Pruvot FR, Hoti E, Kambakamba P, Capobianco I, Nadalin S, Fernandes ESM, Kron P, Lodge P, Olthof PB, van Gulik T, Castro-Benitez C, Adam R, Machado MA, Teutsch M, Li J, Scherer MN, Schlitt HJ, Ardiles V, de Santibañes E, Brusadin R, Lopez-Lopez V, Robles-Campos R, Malagó M, Hernandez-Alejandro R, Clavien PA. First Long-term oncologic results of the ALPPS procedure in a large cohort of patients with colorectal liver metastases. Annals of surgery 2020; 272: 793-800. Copyright© 2020 Wolters Kluwer Health, Inc.